Investment Overview - INVL Private Equity Fund II, the largest private equity fund in the Baltics, has partnered with the International Finance Corporation (IFC) and Accession Capital Partners (ACP) to invest in POLMED, a leading private healthcare provider in Poland [1] - The investment aims to provide expansion capital for POLMED to acquire KN Group, a prominent oncology center, marking one of the first acquisitions for INVL Private Equity Fund II [1] Company Profile: POLMED - Founded in 1999, POLMED has become one of Poland's leading private healthcare groups, generating revenues exceeding EUR 100 million in 2024 [2][10] - The company operates a network of 38 facilities and employs around 2,000 staff, serving over 4 million patients annually and collaborating with more than 4,000 medical partners [2][10] Acquisition Details - The target for acquisition, KN Group, includes Radomskie Centrum Onkologii, Gamma Knife Centre, and Radom Family Centre, which collectively operate three facilities and employ over 700 people [3] - KN Group is recognized for its high-quality oncology services and is led by renowned neurosurgeons who will continue their roles post-acquisition [3] Strategic Implications - The acquisition is subject to regulatory approval from the Polish Office of Competition and Consumer Protection [4] - POLMED's leadership will remain intact, with the founder and president, Radosław Szubert, and co-founder, Romuald Magdoń, retaining majority ownership [4] - The partnership is expected to enhance POLMED's service offerings and improve patient comfort during diagnostics and therapy [5] Investor Insights - The investment consortium believes that with the right support, POLMED can achieve significant growth and become a national leader in healthcare [6] - IFC aims to assist POLMED in transforming into a digitally enabled healthcare platform, expanding access to quality care in Poland [6] About INVL Private Equity Fund II - The fund aims to build a diversified portfolio by acquiring significant stakes in high-growth companies, with investments ranging from EUR 10 million to EUR 60 million [8] - Managed by INVL Asset Management, the fund focuses on opportunities in the Baltic countries, Poland, Romania, and the broader European Union [8] About Accession Capital Partners (ACP) - ACP has been active in Central Europe since 2000 and has raised over EUR 1.2 billion across five dedicated growth capital funds [12] - The firm is backed by reputable institutional investors, including the European Investment Fund and the International Finance Corporation [12]

Core Insights - Telix Pharmaceuticals shows strong sales growth in imaging diagnostics, indicating a positive investment outlook [1] Company Analysis - The company has a solid foundation in biochemistry and clinical trials, enhancing its credibility in the biotech sector [1] - The focus on educating investors about the science behind the business reflects a commitment to transparency and informed decision-making [1] Industry Context - The biotech industry is characterized by its complexities, necessitating thorough due diligence to avoid investment pitfalls [1]